// App-Quantinova.ai

: Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Researchers

Presenter

  • Alexis Talbot

Principal Investigators

  • Solène Weill

  • Eléonore Fox

  • Léa Meunier

  • Guillaume Appé

  • Camille Marijon

  • Abdelkader Behdenna

  • Arun P Wiita

  • Akpéli Nordor

  • Justin Eyquem

Medical Centers

  • Department of Medicine, University of California, San Francisco, San Francisco, CA

  • Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA

  • Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA

  • Epigene Labs, Paris, France

Locations

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Cluster of Differentiation 38

  • Cytokine

  • Cluster of differentiation 8A

  • Integrin beta 7

  • Integrin beta 7

  • Interleukin 6

  • Apparent diffusion coefficient

Drug/Treatment

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • daratumumab Intravenous

  • Interleukin

  • Bortezomib

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved